Nephromag (Buffered Phosphate Solution | Mertiatide)

Buffered Phosphate Solution, the active ingredient in Nephromag, is a pharmaceutical solution presented as an intravenous preparation for infusion use. It is employed to manage phosphate balance in clinical settings. GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Nephromag provides phosphate supplementation for conditions where phosphate balance is disrupted. - Hypophosphatemia: restores serum phosphate levels in patients with low phosphate. - Renal replacement therapy: supplies phosphate during dialysis to maintain electrolyte homeostasis. - Metabolic acidosis correction: contributes buffering capacity to assist in pH regulation during critical care.

Nephromag may be associated with a range of adverse reactions.

Common Side Effects: - Hyperphosphatemia: elevated serum phosphate levels. - Hypocalcemia: reduced calcium concentrations secondary to phosphate binding. - Infusion site irritation: redness or discomfort at the injection site. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Flushing: temporary warmth or redness of the skin.

Serious or Rare Side Effects: - Metastatic calcification: calcium‑phosphate deposition in soft tissues. - Cardiac arrhythmia: rhythm disturbances linked to electrolyte shifts. - Severe allergic reaction: anaphylaxis or hypersensitivity. - Renal failure exacerbation: worsening kidney function in susceptible patients. - Hemodynamic instability: sudden blood pressure changes during infusion. - Seizures: neurologic events related to electrolyte imbalance.

Nephromag should be used with careful clinical monitoring. - Serum phosphate monitoring: check levels before and during therapy. - Calcium balance: assess calcium status to avoid hypocalcemia. - Renal function assessment: evaluate kidney performance prior to infusion. - Hyperphosphatemia avoidance: do not administer to patients with already high phosphate. - Infusion rate control: administer slowly to reduce risk of cardiovascular effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nephromag can interact with other agents that affect electrolyte balance.

Major Interactions (Avoid): - Calcium supplements: may precipitate calcium‑phosphate complexes. - Antacids containing aluminum or magnesium: can interfere with phosphate absorption. - Vitamin D analogues: potentiate hyperphosphatemia risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal phosphate loss, requiring dose adjustment. - ACE inhibitors: may affect renal handling of phosphate. - Bisphosphonates: combined effect on bone mineral metabolism. - Parathyroid hormone analogues: alter calcium‑phosphate dynamics.